Innoviva Inc (INVA) reported quarterly earnings results on Thursday, Jul-28-2016. The company reported $0.13 EPS for the quarter. Analysts had a consensus estimate of $0.13. The company posted revenue of $32.47 million in the period, compared to analysts expectations of $30.63 million. The company’s revenue was up 204.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.07 EPS.
In a different news, on May 20, 2016, James L Tyree (director) sold 813 shares at $10.47 per share price.
Innoviva Inc. formerly Theravance Inc. is an asset management company that is focused on the development commercialization and financial management of bio-pharmaceuticals. The Company is focused on managing its respiratory assets partnered with Glaxo Group Limited (GSK) including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol UMEC/VI) with the intention of providing capital returns to stockholders. Its RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of vilanterol (VI) a long-acting beta2 agonist (LABA) and fluticasone furoate (FF) an inhaled corticosteroid (FF/VI) delivered through the ELLIPTA dry powder inhaler. Its ANORO ELLIPTA is a dual bronchodilator consisting of umeclidinium (UMEC) a long-acting muscarinic antagonist (LAMA) and vilanterol (VI) which is used for the treatment of chronic obstructive pulmonary diseases (COPD).